Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
NEW ORLEANS — Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, the phase III TRANSCEND-T2D-1 trial…
